Both of these processes may play an important role in tumor progression and drug resistance, and preclinical evidence indicates that blocking IL-25 signaling through its receptor (IL-17Rb) using a mAB may be an effective therapeutic route in PDAC [73]. This evidence concerns the gene IL25 and neoplasm.